<p>Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.</p>

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

Share Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

Sign up to save your podcasts

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

More shows like Hematologic Oncology Update

JAMA Editors' Summary

Gastrointestinal Cancer Update

Lung Cancer Update

Prostate Cancer Update

Breast Cancer Update

Gynecologic Oncology Update

Dermatologic Oncology Update

NEJM This Week

Research To Practice | Oncology Videos

The Hematologist

JAMA Clinical Reviews

Annals On Call Podcast

Blood Podcast

Oncology Today with Dr Neil Love

WolverHeme Happy Hour

Two Onc Docs

Blood Cancer Talks